KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Non Operating Income: 2012-2024

Historic Non Operating Income for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to -$3.3 million.

  • Travere Therapeutics' Non Operating Income fell 40.37% to $783,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.5 million, marking a year-over-year decrease of 164.26%. This contributed to the annual value of -$3.3 million for FY2024, which is 127.59% down from last year.
  • Travere Therapeutics' Non Operating Income amounted to -$3.3 million in FY2024, which was down 127.59% from $12.0 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Non Operating Income registered a high of $12.0 million during FY2023, and its lowest value of -$17.5 million during FY2021.
  • In the last 3 years, Travere Therapeutics' Non Operating Income had a median value of -$3.3 million in 2024 and averaged -$877,333.
  • As far as peak fluctuations go, Travere Therapeutics' Non Operating Income spiked by 206.05% in 2023, and later tumbled by 127.59% in 2024.
  • Yearly analysis of 5 years shows Travere Therapeutics' Non Operating Income stood at -$12.6 million in 2020, then tumbled by 38.26% to -$17.5 million in 2021, then spiked by 35.03% to -$11.3 million in 2022, then skyrocketed by 206.05% to $12.0 million in 2023, then tumbled by 127.59% to -$3.3 million in 2024.